Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$44.63 USD
+0.18 (0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $44.62 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Earnings Yield (TTM)
The company's trailing twelve month (TTM) Earning Yield is used to determine whether the company is undervalued or overvalued. The Earning yield an indicator of the company's earnings and the price paid for the stock. The calculation is the inverse of the P/E ratio. The most common use of the Earnings ratio is to compare it to other stocks and to compare the yields to the 10 Year T-Bill. If earnings go up, the yield goes up. If earnings go down, so does the yield. For example: If the yield on the S&P 500 is greater than the 10 Year T-Bill, stocks would be considered undervalued.
TNDM 44.63 +0.18(0.40%)
Will TNDM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNDM
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for TNDM
Embecta Corp.: Navigating Through A Changing Landscape
Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin
Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union
Three Buys, three Sells, one Hold by Oppenheimer analysts
Three ‘buys,’ three ‘sells,’ and a ‘hold,’ by Oppenheimer analysts